AFROCENTRIC INVESTMENT CORPORATION LIMITED - Update to announcement of dealing in securities by directors of a major subsidiary

Update to announcement of dealing in securities by directors of a major subsidiary

AfroCentric Investment Corporation Limited
(Incorporated in the Republic of South Africa)
(Registration number 1988/000570/06)
JSE Code: ACT ISIN: ZAE000078416
("AfroCentric")


UPDATE TO ANNOUNCEMENT OF DEALING IN SECURITIES BY DIRECTORS OF A MAJOR
SUBSIDIARY

Shareholders are referred to the announcement released on SENS on 11 December 2025 (the
"previous announcement") relating to the vesting of awards made under the 2017 Long Term Incentive
Plan in November 2020 and 2021, as well as the 2022 Forfeitable Share Scheme in November 2022,
which awards were due to vest in November 2025. Shareholders are advised that the number of
vested shares, as disclosed in the previous announcement was incorrect in that it failed to take into
account the reduced number of shares that vested under the 2022 Forfeitable Share Scheme.

The following information is applicable to the vesting of awards made to the directors of a major
subsidiary under the 2017 Long Term Incentive Plan as well as the Forfeitable Share Plan, and
includes the reduced number of shares that vested under the Forfeitable Share Plan.


 Name of Director                            Aklaaq Mahmood

 Designation:                                Executive Director of Medscheme, a major subsidiary of
                                             AfroCentric

 Date of transaction:                        1 December 2025

 Nature of transaction:                      Vesting of awards made under the 2017 Long Term
                                             Incentive Plan in November 2020 and 2021, as well as the
                                             2022 Forfeitable Share Scheme in November 2022, which
                                             awards were due to vest in November 2025

 Class of securities:                        Ordinary shares

 Number of securities:                       251 667

 Notional value of transaction (based on     R339 750.45
 an implied price of R1.35 per share,
 being the closing price on 28 November
 2025)

 Nature of interest:                         Direct Beneficial

 Clearance obtained:                         Yes


 Name of Director                            Fezeka Nompumza

 Designation:                                Executive Director of Medscheme, a major subsidiary of
                                             AfroCentric

 Date of transaction:                        1 December 2025

 Nature of transaction:                      Vesting of awards made under the 2017 Long Term
                                             Incentive Plan in November 2021, and the 2022 Forfeitable
                                             Share Scheme in November 2022, which awards were due
                                             to vest in November 2025
 Class of securities:                        Ordinary shares

 Number of securities:                       128 333

 Notional value of transaction (based on     R173 249.55
 an implied price of R1.35 per share,
 being the closing price on 28 November
 2025)

 Nature of interest:                         Direct Beneficial

 Clearance obtained:                         Yes


Johannesburg

26 January 2026

JSE Sponsor to AfroCentric
Questco Corporate Advisory Proprietary Limited

Date: 26-01-2026 04:30:00
Produced by the JSE SENS Department. The SENS service is an information dissemination service administered by the JSE Limited ('JSE'). 
The JSE does not, whether expressly, tacitly or implicitly, represent, warrant or in any way guarantee the truth, accuracy or completeness of
 the information published on SENS. The JSE, their officers, employees and agents accept no liability for (or in respect of) any direct, 
indirect, incidental or consequential loss or damage of any kind or nature, howsoever arising, from the use of SENS or the use of, or reliance on,
 information disseminated through SENS.